Online inquiry

IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10029MR)

This product GTTS-WQ10029MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10029MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ821MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ11234MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ3416MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ4599MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ1060MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ3956MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ9449MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ4003MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BGB-A317
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW